SULT2B1

Across TCGA pan-cancer cohorts, SULT2B1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SULT2B1 data layer compared with 27 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SULT2B1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SULT2B1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where SULT2B1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.289	0.576	.001	66	view →
HNSC	OS	Quartile	IV	0.953	0.608	.003	43	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.631	.002	20	view →
UCEC	DFS	Quartile	All	1.000	0.808	.018	10	view →
CCRCC	DFS	Tertile	II,III,IV	0.454	0.804	.035	4	view →
LUAD	DFS	Median	All	0.861	0.965	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SULT2B1–PDAC (DFS)

Open the PDAC breakdown →